glp-1 drugs common side effects 6 of Taking Medication Your guide to GLP-1 side

Description

However, the research is still early, and long-term studies specifically examining nerve health in semaglutide users have not been completed

Please read our guidelines for opinion pieces before submitting an Op-Ed

Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist: Efficacy in Phase 3 Clinical Trials Based on promising results from Phase 1 and 2 clinical trials, a Phase 3 clinical trial program of the dual GIP/GLP-1 RA, tirzepatide (LY3298176, Eli Lilly and Company, Indianapolis, IN), was started

Those with significant medical co-morbidities, prior CSF diversion procedures, neurovascular stenting or optic nerve sheath fenestration, those currently using GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors or taking drugs that could reduce ICP were excluded

40 During dose escalation in the clinical trials, subjects were allowed to remain at a GLP-1 dose for up to 8 weeks, as needed, to allow GI side effects to dissipate